MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
23.76
+1.18
+5.23%
After Hours: 23.76 0 0.00% 17:43 02/06 EST
OPEN
23.15
PREV CLOSE
22.58
HIGH
23.98
LOW
22.33
VOLUME
818.65K
TURNOVER
--
52 WEEK HIGH
30.50
52 WEEK LOW
14.40
MARKET CAP
1.58B
P/E (TTM)
-7.0258
1D
5D
1M
3M
1Y
5Y
1D
Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX
NASDAQ · 2d ago
Weekly Report: what happened at CLDX last week (0126-0130)?
Weekly Report · 5d ago
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
TipRanks · 01/30 16:30
2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%
Barchart · 01/27 15:02
Weekly Report: what happened at CLDX last week (0119-0123)?
Weekly Report · 01/26 09:53
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
TipRanks · 01/21 16:37
Weekly Report: what happened at CLDX last week (0112-0116)?
Weekly Report · 01/19 09:57
MoneyShow's Best Investment Ideas For 2026: Part 3
Seeking Alpha · 01/13 20:20
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.